



10553608 - GAU: 1633

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/553608
		Filing Date	October 18, 2005
		First Named Inventor	Richard L. BOYD
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet	1	of	10
		Attorney Docket Number	0286336.00160US1/NOR-021US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-20040241842-A1	12-02-2004	Boyd	
	AB*	US-20040259803	12-23-2004	Boyd	
	AC*	US-20040013641-A1	01-22-2004	Boyd	
	AD*	US-20050042679	02-24-2005	Boyd et al.	
	AE*	US-3,972,859	08-03-1976	Fujino et al.	
	AF*	US-4,003,884	01-18-1977	Konig et al.	
	AG*	US-4,008,209	02-15-1977	Fujino et al.	
	AH*	US-4,010,149	03-01-1977	Baba et al.	
	AI*	US-4,024,121	05-17-1977	Schally et al.	
	AJ*	US-4,100,274	07-11-1978	Dutta et al.	
	AK*	US-4,128,638	12-05-1978	Moody	
	AL*	US-4,234,571	11-18-1980	Nestor et al.	
	AM*	US-4,490,291	12-25-1984	Fujino	
	AN*	US-4,642,332	02-10-1987	Folkers et al.	
	AO*	US-4,775,361	10-04-1988	Jacques et al.	
	AP*	US-4,992,421	02-12-1991	De et al.	
	AQ*	US-5,061,620	10-29-1991	Tsukamoto et al.	
	AR*	US-5,144,019	09-01-1992	Rossi et al.	
	AS*	US-5,258,492	11-02-1993	Schally et al.	
	AT*	US-5,434,136	07-18-1995	Mathias	
	AU*	US-5,506,207	04-09-1996	Rivier et al.	
	AV*	US-5,614,187	03-25-1997	Sachs	
	AW*	US-5,624,823	04-29-1997	Sachs et al.	
	AX*	US-5,658,564	08-19-1997	Sykes et al.	
	AY*	US-5,658,892	08-19-1997	Flotte et al.	
	AZ*	US-5,736,524	04-07-1998	Content et al.	
	AA1*	US-5,760,000	06-02-1998	Habibi	
	AB1*	US-5,814,617	09-29-1998	Hoffman et al.	
	AC1*	US-5,876,708	03-02-1999	Sachs	
	AD1*	US-6,030,833	02-29-2000	Seebach et al.	
	AE1*	US-6,103,694	08-15-2000	Mardiney et al.	
	AF1*	US-6,296,846	10-02-2001	Sachs et al.	
	AG1*	US-6,315,772	11-13-2001	Marchitto et al.	
	AH1*	US-6,558,663	05-06-2003	Seebach et al.	
	AI1*	US-6,248,329	06-19-2001	Chandrashekar et al.	
	AJ1*	US-6,492,145	12-10-2002	Lowrie	
	AK1*	US-6,306,651	10-23-2001	Sachs	
	AL1*	US-6,251,099	06-26-2001	Kollias et al.	
	AM1*	US-6,056,738	05-02-2000	Marchitto et al.	
	AN1*	US-5,985,892	11-16-1999	Walsh et al.	
	AO1*	US-5,839,446	11-24-1998	Waner et al.	
	AP1*	US-5,811,275	09-22-1998	Wong-Staal et al.	
	AQ1*	US-5,741,706	04-21-1998	Leavitt et al.	
	AR1*	US-5,681,559	10-28-1997	DiGiusto et al.	
	AS1*	US-5,658,822	08-19-1997	Wu et al.	
Examiner Signature				Date Considered	

US1DOCS 5758448v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/553608	
			Filing Date	October 18, 2005	
			First Named Inventor	Richard L. BOYD	
			Art Unit	Not Yet Assigned	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	10	Attorney Docket Number	0286336.00160US1/NOR-021US

	AT1*	US-5,643,252	07-01-1997	Waner et al.	
	AU1*	US-5,614,502	03-25-1997	Flotte et al.	
	AV1*	US-5,559,703	09-24-1996	Iwata et al.	
	AW1*	US-5,410,016	04-25-1995	Hubbell et al.	
	AX1*	US-5,399,493	03-21-1995	Emerson et al.	
	AY1*	US-5,199,942	04-06-1993	Gillis	
	AZ1*	US-5,073,624	12-17-1991	Coy et al.	
	AA2*	US-5,003,011	03-26-1991	Coy et al.	
	AB2*	US-4,866,160	09-12-1989	Coy et al.	
	AC2*	US-4,656,247	04-07-1987	Folkers et al.	
	AD2*	US-4,608,251	08-26-1986	Mia	
	AE2*	US-4,275,001	06-23-1981	Konig et al.	
	AF2*	US-4,218,439	08-19-1980	Rivier et al.	
	AG2*	US-4,118,483	10-03-1978	Konig et al.	
	AH2*	US-4,089,946	05-16-1978	Foell et al.	
	AI2*	US-4,018,726	04-19-1977	Schally et al.	
	AJ2*	US-4,010,125	03-01-1977	Schally et al.	
	AK2*	US-4,005,063	01-25-1977	Gendrich et al.	
	AL2*	US-3,992,365	11-16-1976	Beddell et al.	
	AM2*	US-20050043245	02-24-2005	Siler-Khodr	
	AN2*	US-20050020524	01-27-2005	Boyd	
	AO2*	US-20040265285	12-30-2004	Boyd	
	AP2*	US-20040258672-A1	12-23-2004	Boyd	
	AQ2*	US-20040132179	07-08-2004	Boyd	
	AR2*	US-20040018180-A1	01-29-2004	Boyd	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.*	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code*	Number* Kind Code* (if known)			
	BA	WO-00/62657		10-26-2000	MONASH UNIVERSITY	
	BB	WO-93/15722		08-19-1993	SYNTEX (USA) INC.	
	BC	EP-217659		04-25-1990	EASTERN VIRGINIA MEDICAL AUTHORITY	
	BD	WO-94/26877		11-24-1994	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	
	BE	WO-01/74377		10-11-2001	SILER-KHODR, KHODR	
	BF	WO-92/19746		11-12-1992	CSL LIMITED, COX, John, Cooper, EDWARDS, Stirling, John	
	BG	WO-01/34815		05-17-2001	CAMBRIA BIOSCIENCES, LLC	
	BH	WO-96/22766		08-01-1996	TAKEDA CHEMICAL INDUSTRIES, LTD.	
	BI	GB-9112825		07-31-1991	IMPERIAL CHEMICAL INDUSTRIES PLC	
	BJ	WO-96/33282		10-24-1996	CHIRON VIAGENE, INC.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

US100CS 5758448v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.L./

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/553608
				Filing Date	October 18, 2005
				First Named Inventor	Richard L. BOYD
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	of	10	Attorney Docket Number	0286336.00160US1/NOR-021US

BK	WO-96/33281	10-24-1996	CHIRON VIAGENE, INC., SYSTEMIX		
BL	WO-98/23325	06-04-1998	THE GENERAL HOSPITAL CORPORATION		
BM	DK-2509783	09-11-1975	TAKEDA CHEMICAL INDUSTRIES, LTD. OSAKA, JP		
BN	WO-99/32619	07-01-1999	THE CARNEGIE INSTITUTE OF WASHINGTON ET AL		
BO	WO-88/01176	02-25-1988	BUNGE (AUSTRALIA) PTY, LTD., BRANDON, Malcolm, Roy		
BP	EP-413209	02-20-1991	ABBOTT LABORATORIES		
BQ	EP-181236	05-14-1986	PITMAN-MOORE, INC		
BR	WO-02/31110	04-18-2002	BOYD		
BS	WO-99/29728	06-17-1999	UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE		
BT	WO-98/08533	03-05-1998	PEPTECH LIMITED		
BU	EP-364819	04-25-1990	THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND		
BV	WO-94/26285	11-24-1994	THE GENERAL HOSPITAL CORPORATION		
BW	GB-9112859	07-31-1991	IMPERIAL CHEMICAL INDUSTRIES PLC		
BX	WO-99/53050	10-21-1999	COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION		
BY	AU-76177/91	11-19-1992	COMMONWEALTH SERUM LABORATORIES LIMITED		
BZ	FR-7923545	09-21-1979			
BA1	WO-95/08105	03-23-1995	SYSTEMIX, INC.		
BB1	WO-96/14853	03-23-1996	UNIVERSITY OF WASHINGTON, FRED HUTCHINSON CANCER RESEARCH CENTER		
BC1	AU-56394/94	09-01-1994	ORTHO PHARMACEUTICAL CORPORATION		

*EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/553608
				Filing Date	October 18, 2005
				First Named Inventor	Richard L. BOYD
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	4	of	10	Attorney Docket Number	0286336.00160US1/NOR-021US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ^o
	CA	Ali et al., (2000) Transplantation 69:221	
	CB	Amado et al., (1999) Front. Biosci. 4:D468-475	
	CC	Andrew et al., (2001) J. Immunol. 166(3): 1524-1530	
	CD	Aspinall, et al., (2000) Vaccine 18:1629	
	CE	Atassi et al., (2001) Crit. Rev. Immunol. 21:1	
	CF	Bach (1983) Birth Defects Original Article Ser. 19(3): 245-253	
	CG	Banerjee et al., (1994) Stem Cells 12:378	
	CH	Basch, (1990) Aging: Immunology and Infectious Disease, Vol. 2, No. 4, 229-235	
	CI	Belhadj et al., "Hepatosplenic gamma-delta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: Report of a Series of 21 Patients," Blood, 2003, pp. 4261-4269, Vol. 102.	
	CJ	Berzins et al., (1999) Proc. Natl. Acad. Sci. USA (17): 9787-9791	
	CK	Bloom et al., (1993) Science 257, 1055	
	CL	Bodey et al., (1997) In Vivo 11(5): 421-440	
	CM	Bolotin et al., (1996) Blood 88:1887	
	CN	Bonyhadi et al., (1997) J. Virology 71:4707-4716	
	CO	Boyd et al., (1993) Immunology Today 14:445	
	CP	Capecchi, (1980) Cell 22:479-488	
	CQ	Castle, (2000) Clin Infect Dis 31(2): 578-585	
	CR	Coleman et al., (1989) Ultrasound Med. Biol. 15:213-227	
	CS	Davis et al. (1998) Hum. Gene Ther., p. 1197-207	
	CT	Denis et al., (1998) Infection and Immunity, (66)4:1527-1533	
	CU	DiGusto et al., (1997) Blood 87:1261	
	CV	Douek et al., (2001) J. Immunol. 167:6663-8	
	CW	Douek et al., (1998) Nature 396:690	
	CX	Doukas et al., (1995) Ultrasound Med. Biol. 21:961	
	CY	Ellis, "New Technologies for Making Vaccines," Chapter 29 of "Vaccines", Plotkin et al., 1998, pp. 568-574.	
	CZ	Engel et al., (1999) Frontiers in Bioscience 4, e26-33	
	CA1	Ernst et al., (1990) J. Immunol. 145:1295	
	CB1	Fabris et al., (1997) Cell Mol. Biol., 43(4): 529-541	
	CC1	Fabris et al., (1995) Aging Apr; 7(2): 77-93	
	CD1	Faltynek et al., (1992) J. Immunol. 149:1276	
	CE1	Fearon et al., (1996) Science 272:50	
	CF1	Fernando et al., (1999) Clin. Exp. Immunol. 115:397	
	CG1	Fitzpatrick et al., (1987) J. Endocr. 113, 51-55	
	CH1	Flynn et al., (1992) Proc. Natl. Acad. Sci. USA 89:12013	
	CI1	Fredrickson et al., (1994) Development and Comparative Immunology 18:251	
	CJ1	Fry et al., (2001) Blood 97(6): 1525-1533	
	CK1	Garrovillo et al., (1999) Transplantation 68:1827	
	CL1	George et al., (1996) Immunol. Today 17:267	
	CM1	Gill et al., (2002) Nat. Immunol. 3:635	
	CN1	Godfrey et al., (1993) Immunol. Today 14:547	
	CO1	Gojo et al., Gene Therapy and Transplantation, (2000), Vol. 69, pp. 1-9.	
	CP1	Goldberg et al., (2003) Abstract, ASBMT, Keystone USA	
	CQ1	Goldberg et al., (2002) Abstract of Oral Presentation, Immunology Group of	
Examiner Signature			Date Considered

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/553608
		Filing Date	October 18, 2005
		First Named Inventor	Richard L. BOYD
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	0286336.00160US1/NOR-021US
Sheet	5	of	10

	Victoria, Beachworth AU	
CR1	Greenstein et al., (1987) J. Endocr., 112, 345-350	
CS1	Grossman, (1985) Science 227: 256-261	
CT1	Hadden, (1998) New York Academy of Sciences, 840: 352-358	
CU1	Haseloff et al., (1988) Nature 334:585	
CV1	Hazenberg et al., (2001) J. Mol. Med. 79:631-40	
CW1	Heliger et al., (1997) Blood 90: 850-857	
CX1	Hirokawa, (1998) "Immunity and Ageing," in PRINCIPLES AND PRACTICE OF GERIATRIC MEDICINE, (M. Pathy, ed.) John Wiley and Sons Ltd.	
CY1	Hirokawa et al., (1975) J. Immunol. 114:1659	
CZ1	Hochberg et al., (2001) Blood 98:1116-21	
CA2	Homo-Delarche et al., (1993) Springer Sem. Immunopathol. 14:221	
CB2	Hu et al., (1993) Int. Immunol. 5:1035-1039	
CC2	Huiskamp et al., (1983) Radiation Research 95:370	
CD2	Igarashi et al., (2001) Proc. Natl. Acad. Sci. USA, 98(26): 15131-15136	
CE2	Jacobson et al., (1999) J. Allergy Clin. Immunol., 104(3): Pt. 1, 653-658	
CF2	Janeway et al., (2001) Immunobiology 5th Ed., p. 325	
CG2	Jenkinson et al., (1985) Transplantat. 39:331	
CH2	Kamradt et al., (2001) N. Engl. J. Med. 344:655-664.	
CI2	Kendall, (1988) "Anatomical and physiological factors influencing the thymic microenvironment," in THYMUS UPDATE I, Vol. 1. (M. D. Kendall, and M. A. Rilter, eds.) Harwood Academic Publishers, p. 27	
CJ2	Kincade et al. (2000) Immunological Reviews, 175: 128-137	
CK2	Kissin et al., (1987) Radiology, 163(1): 67-70	
CL2	Kohen et al., (1998) Developmental Immunology, 5: 277-285	
CM2	Komschlies et al., (1995) J. Leukoc. Biol. Dec.; 58(6): 623-633	
CN2	Krijanovski, et al., (1999) Blood 94:825	
CO2	Kurashima et al., (1995) Int. Immunol. 7:97	
CP2	LeMaoult et al., (2000) J. Immunol. 165:2367	
CQ2	Leposavic et al., (1995) Neuroimmunomodulation 2:100-107	
CR2	Lin et al., (1996) Cancer Res. 56:21	
CS2	Mackall et al., (1998) Eur. J. Immunol. 28: 1886-1893	
CT2	Mackall et al., (1997) Immunology Today, 18(5): 245-251	
CU2	Maraskovsky et al., (1997) Cell 89(7): 1011-9	
CV2	Masera et al., "Is Orchiectomy Indicated Before BMT in Childhood ALL?" Bone Marrow Transplant, 1991, Vol. 8, No. S1, pp 33-35	
CW2	Matera, Neuroimmunomodulation (1997) 4(4): 171-80	
CX2	Medina et al., (2001) Nat. Immunol. 2:718	
CY2	Miller et al., (1976) J. Immunol. 117:1519	
CZ2	Morale et al., (1991) Endocrinology, 128(2): 1073-1085	
CA3	Morrissey et al., (1991) J. Immunol. 146:1547	
CB3	Murasko et al., (2002) Exp. Gerontol. 37:427-439	
CC3	Nicoletti et al., (1993) J. Immunol. 150:543-549	
CD3	Noach et al., (2002) Blood 100:312	
CE3	Oberbeck, (2003) J. Surg Res. 113(2): 248-56	
CF3	Oliver et al., (1995) Urol. Int., 54:226-229	
CG3	Olsen, et al., (2001) J. Clin. Invest. 108:697	
CH3	Oluwole et al., (1993) Transplantation 56:1523-1527	
CI3	Orme et al., (1993) J. Infect. Dis. 167:1481	
Examiner Signature		Date Considered

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/553608
		Filing Date	October 18, 2005
		First Named Inventor	Richard L. BOYD
		An Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet	6	of	10
		Attorney Docket Number	0286336.00160US1/NOR-021US

CJ3	Pacheco et al., (1979) J. Parasitol. 65:414	
CK3	Panoskaltzis et al., (1999) Frontiers in Bioscience 4:457	
CL3	Parkman et al., (1997) Immunol. Rev. 157:73	
CM3	Penit et al., (1996) Dev. Immunol. 5:25	
CN3	Perriman et al., (1992) Gene 113:157	
CO3	Plavec et al., (1996) Gene Ther. p. 717-24	
CP3	Podda et al., (1992) Proc. Natl. Acad. Sci. USA 89:9676	
CQ3	Prasad et al., (1988) J. Clin. Invest. Oct; 82(4): 1202-1210	
CR3	Ranga et al., (1998) Proc. Natl. Acad. Sci. USA 95:1201	
CS3	Renia et al., (1993) J Immunol. 150:1471	
CT3	Robinson, et al. (2000) Adv. Virus Res. 55:1-74	
CU3	Romain et al., (1993) Proc. Natl. Acad. Sci. USA 90:5322	
CV3	Ross et al., "Gene Therapy in the United States: A Five-Year Status Report," Human Gene Therapy, 1996, pp. 1781-1790, Vol. 7.	
CW3	Sato et al., (2004) Br. J. Cancer 90:1334	
CX3	Seder et al., (1994) Annu. Rev. Immunol. 12:635	
CY3	Sempowski et al., (2002) Mol. Immunol. 38:841-84	
CZ3	Shaffer et al., (2003) Lancet Oncol. 4:407	
CA4	Shortman et al., (1990) Seminars in Immuno. 2:3	
CB4	Shull et al., (1992) Nature 359:693	
CC4	Smithson et al., (1995) J. Immunol. 155:3409	
CD4	Soares et al., J. Immunol. (1998) 161:5909-5917	
CE4	Starzl et al., (1992) Lancet 339:1579	
CF4	Stern et al., (1989) Corneal Laser Ablation, 107: 587-592	
CG4	Storek et al., (2001) Blood 98:3505	
CH4	Suda et al., (1991) J. Immunol. 146:3068	
CI4	Takeoka et al., (1999) Clin. Immunol. 90:388-398	
CJ4	Tang et al., (1997) J. Immunol. 159:117	
CK4	Tanghe et al., (2000) Infection and Immunity 68(7): 3854-3860	
CL4	Thurmond et al., (2000) Endocrinol. 141:2309	
CM4	Thomas-Vaslin et al., (1997) P.N.A.S. (U.S.A.) 94:4598-4603	
CN4	Tomita et al., (1994) J. Immunol. 153:1087-1098	
CO4	Ulmer et al., (1993) Science 259:1745	
CP4	Utsuyama et al. (1989) Mech. of Ageing Dev. 175-185	
CQ4	van Ewijk et al., (1980) J. Histochem. Oct 28(10): 1089	
CR4	Vickery et al., (1984) LHRH AND ITS ANALOGS: CONTRACEPTIVE & THERAPEUTIC APPLICATIONS (Vickery et al., eds.) MTP Press Ltd., Lancaster, PA	
CS4	Viselli et al., (1997) Cellular Immunology 182, 99-104	
CT4	Von Freeden-Jeffry et al., (1995) J. Exp. Med. 181:151	
CU4	Wang et al., (2003) Br. J. Cancer 88:887	
CV4	Weinberg et al., (1995) Biol. Blood Marrow Transplant 1 (1): 18-23	
CW4	Weiss et al., (1992) J. Immunol. 149:2103	
CX4	Weyand et al., (1998) Mech. Age. Dev. 102: 131-147	
CY4	Wiles et al., (1992) Eur. J. Immunol. 22:1037	
CZ4	Windmill et al. (1993) Reprod. Fertil. Dev. 5, 73-81	
CA5	Woffendin et al., (1994) Proc. Natl. Acad. Sci. USA, 91:11581	
CB5	Wu et al., (1996) Am. J. Repro. Immunol. 35(6): 510-516	
CC5	Young et al., (1991) Res. Microbiol. 142:55	
CD5	Zlotnik et al., (1995) Curr. Opin. Immunol. 7:206.	
Examiner Signature		Date Considered

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/553608		
		Filing Date	October 18, 2005		
		First Named Inventor	Richard L. BOYD		
		An Unit	Not Yet Assigned		
		Examiner Name	Not Yet Assigned		
Sheet	7	of	10	Attorney Docket Number	0286336.00160US1/NOR-021US

CE5	Zhang et al., (1999) J. Exp. Med. 190:725
CF5	Yang et al., (1994) "The Particle Bombardment System for Mammalian Gene Transfer," in PARTICLE BOMBARDMENT TECHNOLOGY FOR GENE TRANSFER (Yang, N.-S. and Christou, P., eds.), Oxford University Press, New York, pp. 117-141
CG5	Woffendin et al., (1996) Proc. Natl. Acad. Sci. USA, 93:2889
CH5	Windmill et al., (1998) Tissue Cell 30(1): 104-111
CI5	Wilson et al., (1995) Blood 85:1535
CJ5	Wiker et al., (1992) Microbiol. Rev. 56: 648
CK5	Weksler et al., (2000) Vaccine 18:1624-1628
CL5	Weiss et al., (1988) Proc. Natl. Acad. Sci. USA 85:573
CM5	Waterhouse et al., (1998) Proc. Natl. Acad. Sci. USA 95:13959
CN5	Waldrop et al., (1998) J. Immunol. 161(10): 5284-95
CO5	Vogelsang et al., "Thalidomide Induction of Bone Marrow Transplantation Tolerance," Transplantation Proceedings, 1987, Vol. XIX, No. 1, pp 2658-2661
CP5	Viselli et al. (1995) Immunology 84: 337-342
CQ5	van Ewijk et al., (1991) Annu. Rev. Immunol. 9:591-615
CR5	Utsuyama et al., (1995) Mech. Ageing Dev. 107-117
CS5	Umesaki et al., (1999) Gynecol. Obstet. Invest. 48:65-8
CT5	Tosi et al., (1982) Clin. Exp. Immunol. Feb; 47(2): 497-504
CU5	Timm et al., (1999) J. Immunol. 162:711
CV5	Thomson et al., (1999) Immunology Today 20(1):27
CW5	THE JORDAN REPORT 2000: ACCELERATED DEVELOPMENT OF VACCINES, published by the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (available at http://www.niaid.nih.gov/publications/pdf/jordan.pdf -last visited Apr. 2004)
CX5	Tanghe et al., (2001) Infection and Immunity, p. 3041-3047
CY5	Talwar, (1999) Immunol. Rev. 171:173-92
CZ5	Suda et al., (1992) J. Immunol. 149(1): 71-76
CA6	Strayer et al., (2002) Therapy 5:33-41
CB6	Storek et al., (1997) Am. J. Hematol. 54:131
CC6	Steffens et al., (2000) Clin. Immunol. 97:95
CD6	Spittler, "Cancer Vaccines: The Interferon Analogy," Cancer Biotherapy, 1995, Vol. 10, pp. 1-3.
CE6	Smithson et al., (1998) J. Immunol. 161:27-35
CF6	Silva et al., (1994) Immunol. 82:244
CG6	Shu et al., (1993) J. Virol. 67:2723
CH6	Shippy et al., (1999) Mol. Biotechnol. 12: 117
CI6	Sempowski et al., (2000) J. Immunology 164: 2180-2187
CJ6	Segeren et al., (1999) Br. J. Haem. 105: 127-130
CK6	Scollay et al., (1980) Eur. J. Immunol. 10:210
CL6	Rossi et al., (2002) Blood 100:682-691
CM6	Rosenzweig et al., (1997) Blood, 90(12): 4822-4831
CN6	Rodrigues et al., (1991) Int. Immunol. 3: 579
CO6	Repique et al., (2002) Infection and Immunity, p. 3318-3323
CP6	Rao et al., (1994) Am. J. Reproductive Immunology, 32:238-247
CQ6	Randle-Barrett et al., (1995) Dev. Immunol. 4:101
CR6	Potter et al., (1984) Proc. Natl. Acad. Sci. USA 81:7161-7165
CS6	Plosker et al., (1994) Drugs 48:930
CT6	Peschon et al., (1994) J. Exp. Med. 180(5): 1955-1960
CU6	Penit et al., (1989) Proc. Natl. Acad. Sci. U.S.A. 86:5547

Examiner Signature	Date Considered
--------------------	-----------------

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
		Application Number	10/553608
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Filing Date	October 18, 2005
		First Named Inventor	Richard L. BOYD
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	0286336.00160US1/NOR-021US
Sheet	8	of	10

CV6	Pawelec et al., (1999) Frontiers in Bioscience 4, 216-269	
CW6	Panoskaltis-Mortari et al., (2000) Blood 96:4350	
CX6	Panarai et al., (1997) Immunol. Today 4: 191-192	
CY6	Ortman et al., (2002) Int. Immunol. 14:813	
CZ6	Oosterwegel et al., (1997) Immunity 6(3): 351-360	
CA7	Olsen et al., "Androgen Deprivation Induces Phenotypic and Functional Changes in the Thymus of Adult Male Mice," Endocrinology, 1991, pp. 2471-2476, Vol. 129, No. 5	
CB7	Olsen et al., (2001) Endocrinol. 142:1278	
CC7	Ohnishi et al., (2003) Int. J. Mol. Med. 1:331	
CD7	Nowak, (1999) New Scientist, pg. 11	
CE7	Nikolic et al., (2000) Blood, 96(3): 1166-1172	
CF7	Nabel et al., (1992) Hum. Gene Ther. 3:649-656	
CG7	Mosley et al., (1998) Cell. Immunol. 189:10	
CH7	Morelli et al., (2001) Semin. Immunol. 13:323-335	
CI7	Mocchegiani et al., (1990) Horm. Res. 33(6): 248-55	
CJ7	Mercader et al., (2001) PNAS 98(25): 14565-14570	
CK7	Matzinger et al., (1989) Nature 338:74-60	
CL7	Masuzawa et al., (1994) J. Clin. Invest. 94:1090	
CM7	Martinez et al., (2003) J. Clin. Invest. 111:1365	
CN7	Mackall et al., (1995) New England J. Med. 332:143	
CO7	Mackall et al., (1997) Immunol. Rev. 160:91	
CP7	Lincz et al., (2001) Leuk. and Lymph. 40: 373	
CQ7	Lewin et al., (2002) Blood 100:2235	
CR7	LeMaoult et al., (1999) J. Immunol. 162:6384-6391	
CS7	Landstrom et al., (1997) Int. J. Cancer 71, 451-455	
CT7	Krug (2004) Sem. Oncol. 31:112	
CU7	Kouro et al., (2001) Blood 97:2708	
CV7	Kojima et al., "Immunosuppressive Therapy Using Antithymocyte Globulin, Cyclosporine, and Danazol With or Without Human Granulocyte Colony-Stimulating Factor in Children With Acquired Aplastic Anemia," Blood, September 15, 2000, Vol. 96, No. 6, pp 2049-2054	
CW7	Kohn et al., (1999) Blood 94:368-371	
CX7	Kirschmann et al., (1992) Cell. Immunol. 139:426	
CY7	Kincade et al., (2002) Immunology, 14: 385-394	
CZ7	Kendall et al., (1990) Cell Tissue Research, 261(3):555-64	
CA8	Junker et al., (1998) Hum Gene Ther. , p. 333-40	
CB8	Jansson et al., (1994) J. Neuroimmunology 53:203-207	
CC8	Jacobson et al., (1994) Endocrinology, Vol. 184(6): 2516-2523	
CD8	Jacobson et al., (1999) Endocrinology, 140(8): 3429-3437	
CE8	Huygen et al., (1992) Infect. Immunity 60:2880	
CF8	Huiskamp et al., (1985) J. Immunol., 134(4): 2161-2171	
CG8	Hsu et al., (2000) Cancer Res. 60:3701	
CH8	Hoffman et al., (1991) Science 252: 520	
CI8	Hobbs et al., (1993) J. Immunol. 150:3602	
CJ8	Hirokawa et al., (1994) Immunology Letters 40:269	
CK8	Hertogh-Huibregts et al., (1990) Mech. Ageing Dev. 53:141-155	
CL8	Heitger et al., (2002) Blood 99:4053-4062	
CM8	Haynes et al., (1999) J. Clin. Invest. 103: 453-460	
CN8	Hannet et al., (1992) Immunol. Today, June; 13(6): 215-218	
CO8	Grossman, (1984) Endocrine Reviews, 5(3): 435-455	
Examiner Signature		Date Considered

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/553608		
		Filing Date	October 18, 2005		
		First Named Inventor	Richard L. BOYD		
		Art Unit	Not Yet Assigned		
		Examiner Name	Not Yet Assigned		
Sheet	9	of	10	Attorney Docket Number	0285336.00160US1/NOR-021US

CP8	Greenstein et al., (1985) J. Endocr. 110, 417-422
CQ8	Graham et al., (1973) Virology 52:456-457
CR8	Goldberg et al., (2002) Abstract/Poster Presentation ASH, Philadelphia USA
CS8	Goldberg et al., (2003) Poster Presentation, ASBMT, Keystone USA
CT8	Godfrey et al., (1990) Immunol. 70:66
CU8	Girasole et al., (1992) J. Clin. Invest. 89:883
CV8	Ghali et al., "Prevention of Hypermenorrhea With Leuprolide in Premenopausal Women Undergoing Bone Marrow Transplantation," American Journal of Hematology, 1993, Vol. 42, pp 350-353
CW8	Garzetti et al., (1996) Obstet. Gynecol. 88: 234-40
CX8	Garrovillo et al., (2001) Am. J. Transplant. 1:129
CY8	Fry, et al., (2001) Trends Immunol. 22(10): 564-571
CZ8	Franke et al., (2000) Infect. Immun. 68:3403
CA9	Flurkey et al., (1992) J. Gerontol. 47:B115
CB9	Fitzpatrick et al., "Reappearance of Thymus of Ageing Rats after Orchidectomy," Journal of Endocrinology, 1985, pp. R17-R19, Vol. 106
CC9	Feldman et al., "Anti-TNF α Therapy is Useful in Rheumatoid Arthritis and Crohn's Disease: Analysis of the Mechanism of Action Predicts Utility in Other Diseases," Transplantation Proceeding, 1998, Vol. 30, pp. 4126-4127.
CD9	Fan et al., (2002) J. Immunol. 168:755-62
CE9	Faith et al., (1991) Immunol. 74:1
CF9	Fabro et al., (1990) J. Appl. Phys. 68:775
CG9	Ezzell NIH Research, "Cancer 'Vaccines': An Idea Whose Time Has Come?" 1995, Vol. 7, pp. 46-49.
CH9	Erben et al., (2001) Horm. Metab. Res. (2001) 33:491
CI9	Ellis et al., (2001) Int. Immunol. 13:553-558
CJ9	Dreger et al., (1993) Blood 81:1404
CK9	Dougherty et al., (1995) Curr. Opin. Cell Biol. 7:399
CL9	Douek et al., (2000) Lancet 355:1875
CM9	Doria et al., (1997) Mech. Age. Dev. 95: 131-142
CN9	DeWit et al., (1994) DNA Seq. 4:267
CO9	Dawe et al., (1993) Springer Semin. Immunopathol. 14:285
CP9	Consolini et al., (2000) Clin. Exp. Immunol. 121(3): 444-447
CQ9	Charoenvit et al., (1991) J. Immunol. 146: 1020
CR9	Carayon et al., (1992) J. Imm. Methods 147:225
CS9	Bruijntjes et al., (1993) Dev. Immunol. 3:113
CT9	Borremans et al., (1989) Infect. Immunity 57:3123
CU9	Bonato et al., (1998) Infection and Immunity, 66(1): 169-175
CV9	Bolotin et al., (1999) Bone Marrow Transplant, 23(8): 783-788
CW9	Bodey et al., (1997) In Vivo 11(4): 351-370
CX9	Berzins et al., (1998) J Exp. Med. 187: 1839
CY9	Belmont et al., (1997) "Methods for Efficient Retrovirus-Mediated Gene Transfer to Mouse Hematopoietic Stem Cells," in Gene Therapy Protocols (P.D. Robbins, ed.), Humana Press, pp. 223-240
CZ9	Bauer et al., (1997) Blood 89:2259-2267
CAA	Batard et al., (2000) J. Cell. Sci. 113:383-90
CBA	Bahnsen et al., (1997) "Method for Retrovirus-Mediated Gene Transfer to CD34+ Enriched Cells," in Gene Therapy Protocols (P.D. Robbins, ed.), Humana Press, pp.249-263
CCA	Atlan-Gepner et al., (1999) Autoimmunity 3:249-260

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

PTO/SB/D8a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/553608
				Filing Date	October 18, 2005
				First Named Inventor	Richard L. BOYD
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	10	of	10	Attorney Docket Number	0286336.00160US1/NOR-021US

	CDA	Aspinall, (1997) J. Immunol. 158:3037	
	CEA	Andrew et al., (2002) Exp. Gerontol. 37:455	
	CFA	Andersen, (1994) Infect. Immunity, 62:2536	
	CGA	Alpdogan et al., (2001) Blood 98:2256	
	CHA	Akashi et al., (1997) Cell 89(7) 1033-1041	
	CIA	Abdoudkhil, et al., (1991) Scand. J. Immunol. 34, 647-653	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Qian Janice LI/ (05/25/2010)	Date Considered	
-----------------------	-------------------------------	--------------------	--